Kindred Biosciences, Inc. announced the appointment of Ernest Mario and Joseph McCracken to its Board of Directors. Dr. Mario brings to KindredBio 50 years of experience in the pharmaceutical industry. He was previously Chief Executive and Deputy Chairman of Glaxo Holdings from 1989 to 1993, then the second-largest drug company in the world. Subsequently, Dr. Mario served as CEO and Chairman of ALZA Corporation and as CEO and Chairman of Reliant Pharmaceuticals. He is currently Chairman of Soleno Therapeutics, a Venture Partner with Pappas Ventures and serves on a number of corporate boards, including Celgene. Dr. Mario earned a B.S. in Pharmacy at Rutgers and his M.S. and Ph.D. in Physical Sciences at the University of Rhode Island. He holds honorary doctorates from URI and Rutgers, the latter of which in 2001 renamed its pharmacy school the Ernest Mario School of Pharmacy. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma where he was responsible for Roche Pharma's global in-licensing and out-licensing activities. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for more than 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. He currently serves on the boards of Alkahest, Inc. Savara Pharmaceuticals, and Regimmune Inc. Dr. McCracken holds a B.S. in Microbiology, an M.S. in Pharmacology, and a Doctor of Veterinary Medicine from Ohio State University.